Exploring disease-drug pairs in Clinical Trials information for personalized drug repurposing
Alvarez-Perez, A.; Prieto-Santamaria, L.; Ugarte-Carro, E.; Otero-Carrasco, B.; Ayuso-Munoz, A.; Rodriguez-Gonzalez, A.
Show abstract
Drug repurposing, the process of finding new uses for existing drugs, has gained considerable attention due to its potential to reduce the time and costs associated with drug development. Personalized drug repurposing, in which drugs are selected based on the characteristics of individual patients, is an emerging approach that holds promise for improving clinical outcomes. In this context, exploring disease-drug pairs in already conducted clinical trials can provide valuable insights to identify promising patient populations for further study that may lead to personalized drug repositioning. Our analysis aims to shed a light into clinical outcomes by selecting the most appropriate repurposed drug based on clinical trials patient groups characteristics, such as age and gender. It also gives information about the state of the clinical trials studying these disease-drug pairs, gathering information about the study type, phase and statistical method used to calculate the p-value of the chosen outcome measurement, among others. Overall, this study highlights the importance of using existing knowledge as an initial framework to facilitate further research, particularly in providing patient-specific information. Furthermore, it underlines the importance of building on previous research to facilitate a comprehensive understanding of the research topic, which can eventually improve patient outcomes.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An interactive retrieval system for clinical trial studies with context-dependent protocol elements 95%
- Application of observational research methods to real-world studies for rare disease drugs: a scoping review protocol 95%
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 94%
Similar papers in this journal
Similar papers in this journal
- Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis 93%
- Core Outcome Set for Clinical Trials of COVID-19 based on Traditional Chinese and Western Medicine 93%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 92%
Similar papers in this journal
- Practical barriers and facilitators experienced by patients, pharmacists and physicians to the implementation of pharmacogenomic screening in Dutch outpatient hospital care – an explorative pilot study 90%
- The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System 89%
- Construction of tongue image-based machine learning model for screening patients with gastric precancerous lesions 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.